Benitec Biopharma Inc. (BNTC)

US — Healthcare Sector
Peers: BPTH  CBIO  DFFN  CAPR  NXTC  EFTR  LABP  APGN  NAVB  ANGN  AMTI  ALRN  VIRI  ZURA  ZVSA  ONCR  APLM  SGTX 

Automate Your Wheel Strategy on BNTC

With Tiblio's Option Bot, you can configure your own wheel strategy including BNTC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BNTC
  • Rev/Share 0.0
  • Book/Share 2.5278
  • PB 6.1754
  • Debt/Equity 0.0098
  • CurrentRatio 14.8036
  • ROIC -0.3069

 

  • MktCap 399619122.0
  • FreeCF/Share -0.4841
  • PFCF -21.386
  • PE -22.7458
  • Debt/Assets 0.0091
  • DivYield 0
  • ROE -0.3719

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation BNTC H.C. Wainwright -- Buy -- $28 Dec. 16, 2024
Initiation BNTC Robert W. Baird -- Outperform -- $30 Dec. 13, 2024
Initiation BNTC Oppenheimer -- Outperform -- $35 Oct. 16, 2024
Initiation BNTC Guggenheim -- Buy -- $17 Sept. 12, 2024

News

Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year?
BNTC
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive

Here is how Benitec Biopharma Limited (BNTC) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.

Read More
image for news Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year?
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why
BNTC
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Read More
image for news Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why
Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet
BNTC
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 83.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet
Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?
BNTC
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Negative

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

Read More
image for news Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
BNTC
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Read More
image for news Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?
BNTC
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

Read More
image for news Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?
Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade
BNTC
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive

The consensus price target hints at an 85% upside potential for Benitec Biopharma (BNTC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More
image for news Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade
What Makes Benitec Biopharma (BNTC) a New Buy Stock
BNTC
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive

Benitec Biopharma (BNTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news What Makes Benitec Biopharma (BNTC) a New Buy Stock
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
BNTC
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital.

Read More
image for news Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable
BNTC
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Benitec Biopharma (BNTC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Read More
image for news Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable

About Benitec Biopharma Inc. (BNTC)

  • IPO Date 2014-06-24
  • Website https://benitec.com
  • Industry Biotechnology
  • CEO Dr. Jerel A. Banks M.D., Ph.D.
  • Employees 16

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.